News All News
Press Contact: Kirsten Mabry | (617) 495-4157
Tag: Licensing
March 21st, 2016
Blavatnik Biomedical Accelerator at Harvard University announces license and collaboration agreement
Research alliance will advance small-molecule therapy for most common form of acute leukemia, targeting proteins involved in transcriptional regulation.
December 23rd, 2015
Targeting fat-tissue hormone may lead to type 2 diabetes treatment
UCB-funded Harvard study describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.
September 16th, 2014
Blavatnik Biomedical Accelerator success story: new hope for neurodegenerative diseases
Professors Dan Finley and Randy King are poised to change the future for those who suffer from neurodegenerative diseases. With the help of OTD’s Biomedical Accelerator, they were able to build on this foundation and advance the frontiers of science and healthcare.
